This article is based on reporting originally published by healthitsecurity.com. Statistics and quotations are sourced from that article and from the organizations cited therein.
The Data Explosion Reshaping Pharmaceutical R&D
Falling costs in genetic testing, combined with the rapid digitisation of clinical records, wearables data, and patient-generated health data, are opening entirely new avenues for drug discovery and precision medicine. The challenge is no longer generating data—it is storing, managing, and extracting value from it at scale.
According to Eric Banks, Senior Director of the Data Sciences and Data Engineering (DSDE) group at the Broad Institute—a research collaboration between Harvard and MIT—the volume of genomic data available for research doubles roughly every eight months. Banks describes this rate as one that “for years has far exceeded Moore’s law,” adding that petabyte-scale datasets are now a prerequisite for solving the hardest medically relevant scientific problems.
To put those numbers in context: as of the time of original reporting, the Broad Institute had generated more than 70 petabytes of genomic data from 100,000 genomes since 2009—a dataset roughly equivalent to 1.2 billion hours of streaming audio.
That figure does not include electronic health record (EHR) data, data from wearable devices, home monitors, or other patient-generated sources that researchers need to assess therapeutic efficacy and adverse effects. The combined data footprint facing a modern pharmaceutical organisation is staggering, and it is growing faster than most on-premise architectures can absorb.
Why On-Premise Infrastructure Struggles to Keep Up
Traditional on-premise data infrastructure was designed for predictable workloads. Pharmaceutical and life sciences data is anything but predictable. Several structural limitations make on-premise a poor fit:
- High upfront capital expenditure. Organisations must purchase server capacity based on anticipated peak usage at the start of a project, often locking in large capital commitments before the true scope of data needs is understood.
- Difficult and expensive scaling. Adding even modest storage capacity requires procuring, provisioning, and integrating new hardware—a slow and costly cycle that cannot keep pace with data volumes doubling every eight months.
- Self-managed security and compliance. Organisations running their own data centres bear sole responsibility for physical security, patch management, access controls, and audit trails—an ongoing operational burden that requires dedicated specialist staff.
- Limited access to advanced analytics tooling. AI and machine learning capabilities must be built or bought separately, with no native integration into the storage layer. This slows the time-to-insight that competitive pharmaceutical R&D demands.
The cumulative effect is that on-premise infrastructure imposes high costs, limited growth potential, and development friction at precisely the moment when research teams need agility most.
How Cloud Addresses Pharma’s Big Data Requirements
Cloud computing inverts the on-premise cost and flexibility model in ways that are particularly well-suited to genomics and clinical research workloads.
Elastic Scalability
Cloud storage and compute resources can be provisioned in minutes and released when no longer needed. Organisations pay only for what they consume, without committing to hardware that may be underutilised for months between major sequencing runs or clinical trials. When a burst of compute power is required—for example, training a machine learning model on a new genomic dataset—capacity is available on demand.
Built-in AI and Machine Learning Services
Major cloud providers have invested heavily in managed AI and machine learning services that integrate directly with cloud storage. Amazon Web Services, for example, released its Comprehend Medical service, which applies natural language processing to unstructured clinical text to extract actionable medical concepts—a capability that would require significant in-house engineering effort to replicate on-premise. Equivalent services exist across competing cloud platforms, lowering the barrier for pharmaceutical organisations to experiment with AI-driven drug discovery and pharmacovigilance workflows.
Disaster Recovery and Data Availability
The Cloud Standards Customer Council (CSCC) white paper on cloud adoption in healthcare notes that cloud service providers routinely deliver higher application availability and more robust disaster recovery capabilities than most organisations can achieve in their own data centres, and at lower overall cost. For pharmaceutical companies managing irreplaceable genomic datasets and clinical trial data, this is a material operational and regulatory advantage.
Reduced Administrative Overhead
Infrastructure management, physical environment maintenance, and security patching are shifted to the cloud provider, freeing internal engineering and data science teams to focus on research workloads rather than hardware operations. The CSCC notes that this translates to “improved responsiveness with internal business partners and decreased administrative overhead.”
Security and Privacy: A Critical Consideration for Genomic Data
Genomic and clinical data carry unique privacy risks that must be addressed explicitly in any cloud strategy. DNA data is inherently identifiable—even when stripped of direct identifiers, it can in principle be re-linked to individuals. Pharmaceutical organisations moving this data to the cloud must navigate:
- Patient consent frameworks that specify permissible uses of genetic data, including research reuse.
- Regulatory requirements such as HIPAA in the United States and GDPR in the European Union, both of which impose strict controls on the handling of health and genetic data.
- Data residency constraints that may limit which cloud regions can be used to store specific datasets.
- Access control and audit logging to demonstrate to regulators and IRBs that data access is appropriately governed.
Cloud providers serving the life sciences sector have invested in compliance frameworks and certifications to address these requirements, but the responsibility for implementing correct controls remains shared between the provider and the customer. A cloud-first strategy for pharma big data must include a rigorous security architecture review, not merely a cost-benefit analysis of storage pricing.
Adoption Trends: Where the Sector Is Heading
According to a HIMSS Analytics survey cited in the original source article, 65 percent of hospitals and health systems were using cloud-based storage and computing technologies as of 2017. Three-quarters of survey participants considered cloud well-suited to serve as a primary data storage hub, and more than 84 percent believed cloud could provide effective disaster recovery and backup services. Cost savings were identified as the strongest motivator for adoption, followed by scalable storage and faster deployment cycles.
The trajectory in pharmaceutical R&D specifically mirrors this broader healthcare trend. The CSCC observes that “the ‘explosion of data’ from next generation sequencing, as well as the growing importance of biologics in the research process, is making cloud computing an increasingly important aspect of R&D,” and that pharma firms “no longer are required to implement the capacity to handle large datasets in their computing facilities, lowering the barrier to entry and increasing the velocity of change.”
Practical Steps for Pharmaceutical Organisations Evaluating Cloud Migration
For engineering and DevOps teams supporting pharmaceutical or life sciences organisations, a successful cloud migration for big data workloads typically involves the following considerations:
- Audit existing data assets and classify by sensitivity. Understand which datasets contain identifiable genomic or clinical information before selecting storage tiers or regions.
- Select a cloud provider with relevant compliance certifications. Look for HIPAA Business Associate Agreement (BAA) coverage, SOC 2 Type II reports, and, where applicable, GDPR Data Processing Agreements.
- Design for elastic compute from the start. Genomics pipelines have highly variable compute requirements. Architect workflows to run on spot or preemptible instances where possible to control costs without sacrificing throughput.
- Integrate managed ML services early. Evaluate managed services for natural language processing of clinical notes, genomic variant analysis, and predictive modelling before committing to building bespoke tooling.
- Implement robust data governance. Define and enforce data lineage, access controls, and retention policies as code to maintain audit trails that satisfy both internal and regulatory requirements.
- Plan for hybrid or multi-cloud scenarios. Some datasets or processing workloads may need to remain on-premise due to contractual, regulatory, or latency constraints. Design integration patterns that support this from the outset.
Summary
Genomic and clinical data volumes are growing at a pace that on-premise infrastructure cannot sustain economically or operationally. Cloud platforms offer pharmaceutical and life sciences organisations the scalability, built-in AI tooling, disaster recovery, and reduced operational overhead needed to compete in precision medicine research. Security and privacy must remain first-class concerns in any cloud architecture for this sector, but the foundational advantages of cloud-based big data platforms are clear. For DevOps and platform engineering teams supporting these organisations, building cloud-native, compliant, and elastic data pipelines is no longer a future-state aspiration—it is a present-day competitive requirement.